Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Daiichi Sankyo Co. Ltd.
DescriptionHistone-lysine N-methyltransferase EZH1/2 dual inhibitor
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationNon-Hodgkin's lymphoma (NHL)
Indication DetailsTreat Non-Hodgkin's lymphoma (NHL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today